Skip to main content
OpenTrials
Completed

NCT Number: NCT07563491

Comparison of Esomeprazole Versus Vonoprazan in Gastroesophageal Reflux Disease

Local literature is deprived of data comparing the effectiveness of esomeprazole and vonoprazan in patients with gastroesophageal reflux disease (GERD). This study was planned with the objective of comparing the effectiveness of esomeprazole versus vonoprazan in patients diagnosed with GERD.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Gastro Esophageal Reflux Deglutition Disorders Digestive System Diseases Esophageal Diseases Esophageal Motility Disorders Gastroesophageal Reflux Gastrointestinal Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Allama Iqbal teaching hospital

Dera Ghazi Khan, Punjab Province, 32200, Pakistan

About this study

Addressing the pressing need for an in-depth understanding and comparison of treatment options for the escalating prevalence of GERD, a condition significantly impacting patients' quality of life, is crucial. The study's results would not only provide local data, but also help doctors choose between esomeprazole and vonoprazan as the best treatment option. This would improve patient care and help doctors make better decisions, which would ultimately lead to better management of GERD and the overall health of patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Any gender
  • Aged 18 to 65 years
  • Presenting with GERD

Exclusion criteria

  • Patients with hepatic, renal, respiratory, or cardiac disease accessed on history and medical records.
  • Any previous history of malignancy accessed from medical records.
  • Pregnancy and Lactation
  • Currently using histamine-2 receptor antagonists, antacids, gastrointestinal motility stimulants, and steroids.
  • History of drug allergy to proton pump Inhibitors (PPIs).

Treatment and study plan

Esomeprazole

Drug

Patients received a once-daily dose of 20 mg of esomeprazole after the evening meal for 4 weeks.

Vonoprazan

Drug

Patients received a once-daily dose of 20 mg of vonoprazan after the evening meal for 4 weeks.

Primary outcomes

  1. Sufficient relief

    Time frame: 4 weeks

    The frequency of patients who achieved sufficient relief was noted.

Sponsors and collaborators

Lead sponsor

Muhammad Aamir Latif

Other

Registry information

Official study title

Comparison of Effectiveness in Patients of Gastroesophageal Reflux Disease Taking Esomeprazole Versus Vonoprazan.

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
May 4, 2026
Registry last updated
May 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.